Johnson & Johnson (JNJ) Change in Cash (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Change in Cash came in at $2.0 billion in Q1 2026, down 86.23% year-on-year from $14.4 billion in Q1 2025, and up 33.9% quarter-over-quarter from $1.5 billion in Q4 2025.
Johnson & Johnson (JNJ) Change in Cash (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Change in Cash across 18 years of filings, most recently posting $2.0 billion for Q1 2026.
- Change in Cash for Q1 2026 came in at $2.0 billion, down 86.23% year-over-year; the trailing twelve-month figure through Mar 2026 was -$16.8 billion (down 229.11% YoY), and the FY2025 annual result was -$4.4 billion, down 295.73% from the prior year.
- Change in Cash came in at $2.0 billion for Q1 2026 at Johnson & Johnson, up from $1.5 billion in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $14.4 billion in Q1 2025 to a low of -$19.9 billion in Q2 2025.
- The 5-year median for Change in Cash is -$346.0 million (2025), against an average of -$29.5 million.
- Across the five-year window, Change in Cash surged 416.55% in 2023 and sank 3244.03% in 2025, its largest moves.
- Johnson & Johnson's Change in Cash stood at -$4.0 billion in 2022, then jumped by 152.96% to $2.1 billion in 2023, then surged by 93.57% to $4.1 billion in 2024, then slumped by 64.17% to $1.5 billion in 2025, then surged by 33.9% to $2.0 billion in 2026.
- The last three Change in Cash figures came in at $2.0 billion (Q1 2026), $1.5 billion (Q4 2025), and -$346.0 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 96,436,181.12 Bn | 96,436,176.16 Bn | 7.76 Bn | -71.45 Mn |
| 2 | Eli Lilly | 1,017.30 Bn | 1,012.01 Bn | 16.22 Bn | -1.99 Bn |
| 3 | Johnson & Johnson | 579.61 Bn | 557.55 Bn | 15.96 Bn | 1.98 Bn |
| 4 | AbbVie | 402.30 Bn | 392.96 Bn | 10.78 Bn | 4.16 Bn |
| 5 | Merck | 294.24 Bn | 288.59 Bn | 12.09 Bn | -9.29 Bn |
| 6 | Amgen | 191.82 Bn | 179.78 Bn | 5.87 Bn | 2.91 Bn |
| 7 | Gilead Sciences | 155.93 Bn | 148.21 Bn | 5.52 Bn | 65.00 Mn |
| 8 | Pfizer | 149.05 Bn | 136.28 Bn | -1.21 Bn | 563.00 Mn |
| 9 | Bristol Myers Squibb | 116.33 Bn | 105.88 Bn | 8.07 Bn | -635.00 Mn |
| 10 | Novartis Ag | 112.59 Bn | 111.90 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 1.98 Bn |
| Dec 28, 2025 | 1.48 Bn |
| Sep 28, 2025 | -346.00 Mn |
| Jun 29, 2025 | -19.90 Bn |
| Mar 30, 2025 | 14.37 Bn |
| Dec 29, 2024 | 4.13 Bn |
| Sep 29, 2024 | -4.90 Bn |
| Jun 30, 2024 | -595.00 Mn |
| Mar 31, 2024 | 3.61 Bn |
| Dec 31, 2023 | 2.13 Bn |
| Oct 1, 2023 | -1.46 Bn |
| Jul 2, 2023 | -5.68 Bn |
| Apr 2, 2023 | 12.74 Bn |
| Jan 1, 2023 | -3.98 Bn |
| Apr 3, 2022 | -4.02 Bn |
| Oct 3, 2021 | 3.27 Bn |
| Jul 4, 2021 | 1.66 Bn |
| Apr 4, 2021 | -1.31 Bn |
| Jan 3, 2021 | -4.98 Bn |
| Sep 27, 2020 | 7.79 Bn |